$RDHL - Aemcolo® and Talicia® in Q4/2019 and Q1/2020

NASDAQ:RDHL   Redhill Biopharma Ltd
• U.S. FDA approval of Talicia® for the treatment of Helicobacter pylori infection in adults
• Strategic partnership with Cosmo Pharmaceuticals, including investment of $36.3 million and exclusive rights to
commercialize Aemcolo® in the U.S. for travelers’ diarrhea
• Accelerating expansion of commercial sales team in the U.S. ahead of planned launches of Aemcolo® and Talicia® in
Q4/2019 and Q1/2020, respectively
• Debt-free balance sheet with approximately $59 million as of October 22, 2019 following the investment by Cosmo

Technically, as long it above 6.1, target it 6.7 and 7 .

Not for a suggestion.